First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study
Background - Results from the JAVELIN Merkel 200 study led to the approval of avelumab [an anti-programmed death-ligand 1 (PD-L1) antibody] for the treatment of metastatic Merkel cell carcinoma (mMCC) in multiple countries and its inclusion in the treatment guidelines as a preferred or recommended t...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
May 2024
|
| In: |
ESMO open
Year: 2024, Jahrgang: 9, Heft: 5, Pages: 1-7 |
| ISSN: | 2059-7029 |
| DOI: | 10.1016/j.esmoop.2024.103461 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.esmoop.2024.103461 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2059702924012298 
|
| Verfasserangaben: | S.P. D’Angelo, C. Lebbé, L. Mortier, A.S. Brohl, N. Fazio, J.-J. Grob, N. Prinzi, G.J. Hanna, J.C. Hassel, F. Kiecker, A. von Heydebreck, G. Güzel & P. Nghiem |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1910582670 | ||
| 003 | DE-627 | ||
| 005 | 20250716213536.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241202s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.esmoop.2024.103461 |2 doi | |
| 035 | |a (DE-627)1910582670 | ||
| 035 | |a (DE-599)KXP1910582670 | ||
| 035 | |a (OCoLC)1528014468 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a D'Angelo, Sandra P. |e VerfasserIn |0 (DE-588)1250189233 |0 (DE-627)1786986043 |4 aut | |
| 245 | 1 | 0 | |a First-line avelumab treatment in patients with metastatic Merkel cell carcinoma |b 4-year follow-up from part B of the JAVELIN Merkel 200 study |c S.P. D’Angelo, C. Lebbé, L. Mortier, A.S. Brohl, N. Fazio, J.-J. Grob, N. Prinzi, G.J. Hanna, J.C. Hassel, F. Kiecker, A. von Heydebreck, G. Güzel & P. Nghiem |
| 264 | 1 | |c May 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 13. Mai 2024 | ||
| 500 | |a Gesehen am 02.12.2024 | ||
| 520 | |a Background - Results from the JAVELIN Merkel 200 study led to the approval of avelumab [an anti-programmed death-ligand 1 (PD-L1) antibody] for the treatment of metastatic Merkel cell carcinoma (mMCC) in multiple countries and its inclusion in the treatment guidelines as a preferred or recommended therapy in this setting. Here, we report 4-year follow-up results from the cohort of patients with mMCC who received avelumab as first-line treatment. - Patients and methods - In part B of JAVELIN Merkel 200, a single-arm, open-label, phase II study, patients with mMCC who had not received prior systemic therapy for metastatic disease received avelumab 10 mg/kg via intravenous infusion every 2 weeks until confirmed disease progression, unacceptable toxicity, or withdrawal. In this analysis, long-term overall survival (OS), patient disposition, and subsequent treatment were analyzed. - Results - In total, 116 patients received first-line avelumab. At the data cutoff (2 February 2022), the median follow-up was 54.3 months (range 48.0-69.7 months). Seven patients (6.0%) remained on treatment and an additional 21 patients remained in follow-up (18.1%); 72 patients (62.1%) had died. The median OS was 20.3 months [95% confidence interval (CI) 12.4-42.0 months], with a 4-year OS rate of 38% (95% CI 29% to 47%). In patients with PD-L1+ or PD-L1− tumors, the 4-year OS rate was 48% (95% CI 26% to 67%) and 35% (95% CI 25% to 45%), respectively. In total, 48 patients (41.4%) received poststudy anticancer drug therapy, most commonly etoposide (20.7%), carboplatin (19.0%), and avelumab (12.1%). - Conclusions - Avelumab first-line monotherapy in patients with mMCC resulted in meaningful long-term OS, which compared favorably with historical studies of first-line chemotherapy. These results further support the role of avelumab as a standard of care for patients with mMCC. | ||
| 650 | 4 | |a avelumab | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a Merkel cell carcinoma | |
| 650 | 4 | |a overall survival | |
| 700 | 1 | |a Lebbé, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mortier, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brohl, A. S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fazio, N. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grob, J. -J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Prinzi, N. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hanna, G. J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hassel, Jessica C. |d 1975- |e VerfasserIn |0 (DE-588)129790702 |0 (DE-627)480399069 |0 (DE-576)29783715X |4 aut | |
| 700 | 1 | |a Kiecker, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a von Heydebreck, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Güzel, G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nghiem, P. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESMO open |d [London] : Elsevier, 2016 |g 9(2024), 5 vom: Mai, Artikel-ID 103461, Seite 1-7 |h Online-Ressource |w (DE-627)84705344X |w (DE-600)2844985-X |w (DE-576)454658516 |x 2059-7029 |7 nnas |a First-line avelumab treatment in patients with metastatic Merkel cell carcinoma 4-year follow-up from part B of the JAVELIN Merkel 200 study |
| 773 | 1 | 8 | |g volume:9 |g year:2024 |g number:5 |g month:05 |g elocationid:103461 |g pages:1-7 |g extent:7 |a First-line avelumab treatment in patients with metastatic Merkel cell carcinoma 4-year follow-up from part B of the JAVELIN Merkel 200 study |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.esmoop.2024.103461 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2059702924012298 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20241202 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 129790702 |a Hassel, Jessica C. |m 129790702:Hassel, Jessica C. |d 910000 |d 911300 |d 50000 |e 910000PH129790702 |e 911300PH129790702 |e 50000PH129790702 |k 0/910000/ |k 1/910000/911300/ |k 0/50000/ |p 9 | ||
| 999 | |a KXP-PPN1910582670 |e 4629776214 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1910582670"],"doi":["10.1016/j.esmoop.2024.103461"]},"name":{"displayForm":["S.P. D’Angelo, C. Lebbé, L. Mortier, A.S. Brohl, N. Fazio, J.-J. Grob, N. Prinzi, G.J. Hanna, J.C. Hassel, F. Kiecker, A. von Heydebreck, G. Güzel & P. Nghiem"]},"recId":"1910582670","physDesc":[{"noteIll":"Illustrationen","extent":"7 S."}],"title":[{"title":"First-line avelumab treatment in patients with metastatic Merkel cell carcinoma","title_sort":"First-line avelumab treatment in patients with metastatic Merkel cell carcinoma","subtitle":"4-year follow-up from part B of the JAVELIN Merkel 200 study"}],"note":["Online verfügbar: 13. Mai 2024","Gesehen am 02.12.2024"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"person":[{"family":"D'Angelo","given":"Sandra P.","role":"aut","display":"D'Angelo, Sandra P."},{"display":"Lebbé, C.","family":"Lebbé","given":"C.","role":"aut"},{"display":"Mortier, L.","family":"Mortier","given":"L.","role":"aut"},{"display":"Brohl, A. S.","given":"A. S.","role":"aut","family":"Brohl"},{"display":"Fazio, N.","role":"aut","given":"N.","family":"Fazio"},{"display":"Grob, J. -J.","role":"aut","given":"J. -J.","family":"Grob"},{"display":"Prinzi, N.","family":"Prinzi","role":"aut","given":"N."},{"display":"Hanna, G. J.","family":"Hanna","given":"G. J.","role":"aut"},{"display":"Hassel, Jessica C.","family":"Hassel","given":"Jessica C.","role":"aut"},{"display":"Kiecker, F.","family":"Kiecker","role":"aut","given":"F."},{"display":"von Heydebreck, A.","role":"aut","given":"A.","family":"von Heydebreck"},{"display":"Güzel, G.","given":"G.","role":"aut","family":"Güzel"},{"display":"Nghiem, P.","role":"aut","given":"P.","family":"Nghiem"}],"relHost":[{"id":{"zdb":["2844985-X"],"eki":["84705344X"],"issn":["2059-7029"]},"part":{"text":"9(2024), 5 vom: Mai, Artikel-ID 103461, Seite 1-7","extent":"7","issue":"5","pages":"1-7","volume":"9","year":"2024"},"name":{"displayForm":["European Society for Medical Oncology"]},"pubHistory":["1.2016 -"],"corporate":[{"display":"European Society for Medical Oncology","role":"isb"}],"title":[{"title_sort":"ESMO open","title":"ESMO open","subtitle":"cancer horizons"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"note":["Gesehen am 13.06.24"],"origin":[{"publisher":"Elsevier ; BMJ","dateIssuedKey":"2016","publisherPlace":"[London] ; London","dateIssuedDisp":"2016-"}],"disp":"First-line avelumab treatment in patients with metastatic Merkel cell carcinoma 4-year follow-up from part B of the JAVELIN Merkel 200 studyESMO open","recId":"84705344X","physDesc":[{"extent":"Online-Ressource"}]}],"origin":[{"dateIssuedDisp":"May 2024","dateIssuedKey":"2024"}]} | ||
| SRT | |a DANGELOSANFIRSTLINEA2024 | ||